Skip to main content
. 2018 Apr 5;2018:4615043. doi: 10.1155/2018/4615043

Figure 3.

Figure 3

Meta-analytic comparison showing (a) incidence of stroke between the TAVR and SAVR group, (b) incidence of acute kidney injury between the TAVR and SAVR group, and (c) incidence of major adverse cardiovascular events between the TAVR and SAVR group.